Apogee Therapeutics (APGE) News Today $37.06 +0.36 (+0.98%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Apogee Therapeutics (NASDAQ:APGE) Shares Down 4.6% - Here's WhyApogee Therapeutics (NASDAQ:APGE) Trading Down 4.6% - Here's WhyJanuary 16 at 2:23 PM | marketbeat.comCritical Review: BioCardia (NASDAQ:BCDA) versus Apogee Therapeutics (NASDAQ:APGE)January 14, 2025 | americanbankingnews.comApogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $732,750.00 in StockJanuary 13, 2025 | americanbankingnews.comInsider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells 15,000 Shares of StockJanuary 11, 2025 | insidertrades.comApogee Therapeutics, Inc. (NASDAQ:APGE) Receives $89.71 Consensus PT from AnalystsJanuary 11, 2025 | americanbankingnews.comApogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 15,000 SharesApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 15,000 shares of the firm's stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $48.85, for a total transaction of $732,750.00. Following the completion of the transaction, the chief executive officer now directly owns 1,309,487 shares in the company, valued at $63,968,439.95. This represents a 1.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.January 10, 2025 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Stock Price Down 9.1% - Should You Sell?Apogee Therapeutics (NASDAQ:APGE) Trading Down 9.1% - What's Next?January 10, 2025 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Receives Average Recommendation of "Buy" from AnalystsShares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) have been given an average rating of "Buy" by the seven research firms that are covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average 12 month price objective among brokerJanuary 8, 2025 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 4,085 SharesJanuary 4, 2025 | insidertrades.comCarl Dambkowski Sells 4,085 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) StockApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 4,085 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $46.94, for a total transaction of $191,749.90. Following the transaction, the insider now owns 255,348 shares of the company's stock, valued at $11,986,035.12. This represents a 1.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.January 3, 2025 | marketbeat.comThis Apogee Therapeutics Insider Increased Their Holding In The Last YearDecember 25, 2024 | finance.yahoo.comGeode Capital Management LLC Increases Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)Geode Capital Management LLC raised its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 11.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 823,839 shares of the company's stock after purchasing aDecember 24, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Stock Price Down 3.2% - Here's WhyApogee Therapeutics (NASDAQ:APGE) Shares Down 3.2% - What's Next?December 20, 2024 | marketbeat.comFranklin Resources Inc. Trims Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)Franklin Resources Inc. decreased its position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 14.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 860,989 shares of the company's stock after sDecember 18, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Stock Price Up 6.1% Following Insider Buying ActivityApogee Therapeutics (NASDAQ:APGE) Trading Up 6.1% After Insider Buying ActivityDecember 17, 2024 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Director Purchases $990,800.00 in StockDecember 17, 2024 | insidertrades.comState Street Corp Has $82.92 Million Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)State Street Corp cut its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 9.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,411,639 shares of the company's stock after selling 149December 17, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Shares Gap Up After Insider Buying ActivityApogee Therapeutics (NASDAQ:APGE) Shares Gap Up on Insider Buying ActivityDecember 16, 2024 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Director Mark C. Mckenna Buys 20,000 SharesApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) Director Mark C. Mckenna purchased 20,000 shares of Apogee Therapeutics stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $49.54 per share, for a total transaction of $990,800.00. Following the acquisition, the director now owns 20,000 shares in the company, valued at approximately $990,800. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.December 16, 2024 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Sees Large Growth in Short InterestApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) was the target of a large increase in short interest in November. As of November 30th, there was short interest totalling 7,360,000 shares, an increase of 11.2% from the November 15th total of 6,620,000 shares. Based on an average trading volume of 458,200 shares, the days-to-cover ratio is currently 16.1 days. Approximately 20.3% of the shares of the stock are short sold.December 15, 2024 | marketbeat.comBarclays PLC Boosts Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE)Barclays PLC boosted its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 369.2% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 365,046 shares of the company's stock after purchasing an additional 287,243 shares during the period. Barclays PLCDecember 15, 2024 | marketbeat.comCarl Dambkowski Sells 4,540 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) StockDecember 14, 2024 | insidertrades.comApogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Recommendation of "Buy" from AnalystsShares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) have received an average recommendation of "Buy" from the eight ratings firms that are presently covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy rating. The average 1-year target pDecember 14, 2024 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 4,540 SharesApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 4,540 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $48.76, for a total transaction of $221,370.40. Following the transaction, the insider now directly owns 258,073 shares in the company, valued at $12,583,639.48. The trade was a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.December 13, 2024 | marketbeat.comWellington Management Group LLP Boosts Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)Wellington Management Group LLP boosted its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 35.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,814,400 sharesDecember 8, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $16.47 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE)Charles Schwab Investment Management Inc. boosted its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 17.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 280,428 shareDecember 8, 2024 | marketbeat.comCarl Dambkowski Sells 6,665 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) StockDecember 7, 2024 | insidertrades.comJanus Henderson Group PLC Boosts Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)Janus Henderson Group PLC increased its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 4,018.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 469,557 shares of the company's stock after puDecember 7, 2024 | marketbeat.comCarl Dambkowski Sells 6,665 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) StockApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 6,665 shares of the firm's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $46.07, for a total transaction of $307,056.55. Following the completion of the sale, the insider now owns 260,798 shares of the company's stock, valued at $12,014,963.86. This trade represents a 2.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.December 6, 2024 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $698,700.00 in StockApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 15,000 shares of the company's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $46.58, for a total value of $698,700.00. Following the completion of the transaction, the chief executive officer now owns 1,324,487 shares of the company's stock, valued at approximately $61,694,604.46. This represents a 1.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.December 6, 2024 | marketbeat.comTD Cowen Sticks to Its Buy Rating for Apogee Therapeutics, Inc. (APGE)December 6, 2024 | markets.businessinsider.comPoint72 Asset Management L.P. Buys 438,036 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)Point72 Asset Management L.P. raised its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 162.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 707,268 shares of the company's stock after purchasing an additional 438,036 shares during the qDecember 5, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Apogee Therapeutics, Inc. (APGE) and TransMedics Group (TMDX)December 4, 2024 | markets.businessinsider.comHighVista Strategies LLC Sells 17,154 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)HighVista Strategies LLC reduced its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 21.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 61,788 shares of the company's stock after sDecember 3, 2024 | marketbeat.comApogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D DayDecember 2, 2024 | globenewswire.comApogee Therapeutics Announces Agenda for Virtual R&D DayNovember 29, 2024 | globenewswire.comBraidwell LP Sells 748,816 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)Braidwell LP lessened its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 31.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,643,226 shares of the company's stock after selling 748,816 shNovember 29, 2024 | marketbeat.comVestal Point Capital LP Acquires Shares of 136,500 Apogee Therapeutics, Inc. (NASDAQ:APGE)Vestal Point Capital LP bought a new stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 136,500 shares of the company's stock, valued at approximately $8,018,000. VesNovember 29, 2024 | marketbeat.comNatixis Advisors LLC Makes New $879,000 Investment in Apogee Therapeutics, Inc. (NASDAQ:APGE)Natixis Advisors LLC bought a new stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 14,968 shares of the company's stock, valued at approximatelyNovember 28, 2024 | marketbeat.comApogee Therapeutics price target raised to $110 from $95 at GuggenheimNovember 27, 2024 | msn.comGuggenheim Issues Positive Forecast for Apogee Therapeutics (NASDAQ:APGE) Stock PriceGuggenheim raised their price target on shares of Apogee Therapeutics from $95.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday.November 27, 2024 | marketbeat.comCanaccord Genuity Initiates Coverage of Apogee Therapeutics (APGE) with Buy RecommendationNovember 26, 2024 | msn.comApogee Therapeutics (NASDAQ:APGE) Now Covered by Analysts at Canaccord Genuity GroupCanaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research report on Monday. They issued a "buy" rating and a $89.00 target price for the company.November 25, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Coverage Initiated by Analysts at Canaccord Genuity GroupCanaccord Genuity Group began coverage on Apogee Therapeutics in a report on Monday. They set a "buy" rating and a $89.00 target price on the stock.November 25, 2024 | marketbeat.comVictory Capital Management Inc. Boosts Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE)Victory Capital Management Inc. boosted its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 121.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 346,358 shares of the company's stock after purchasing an additional 190,092 sharesNovember 19, 2024 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Given Consensus Rating of "Buy" by AnalystsShares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) have been assigned a consensus recommendation of "Buy" from the six ratings firms that are covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12-month pricNovember 19, 2024 | marketbeat.comApogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024November 18, 2024 | globenewswire.comWedbush Forecasts Lower Earnings for Apogee TherapeuticsApogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) - Analysts at Wedbush lowered their FY2024 earnings estimates for Apogee Therapeutics in a report released on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will earn ($3.10) per share for the year, down fNovember 15, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth PlansNovember 14, 2024 | finance.yahoo.comApogee Therapeutics Highlights Pipeline Progress and FinancialsNovember 13, 2024 | markets.businessinsider.com Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address APGE Media Mentions By Week APGE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APGE News Sentiment▼0.460.64▲Average Medical News Sentiment APGE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APGE Articles This Week▼54▲APGE Articles Average Week Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RVMD News Today LNTH News Today BPMC News Today BBIO News Today LEGN News Today ELAN News Today CYTK News Today NUVL News Today GRFS News Today TGTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APGE) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
